Lymphoma
In early June 2024, the results of a Phase I clinical trial for the CD7-CAR-T product PA3-17 in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (r/r T-ALL/LBL) were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.